Skip to content

Amazonian Oil intake on Metabolic Syndrome

Effect of amazonian oil intake on Metabolic Syndrome patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-5d25w3
Enrollment
Unknown
Registered
2019-10-08
Start date
2017-09-11
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome

Interventions

The participants will be separated into four groups. Groups 1 (G1, n= 40), 2 (G2, n= 40) and 3 (G3, n= 40) will be composed by the participants who will receive açai, buriti and Brazil nut oils, respe
Dietary supplement
G07.203.300.456

Sponsors

Lívia Martins Costa e Silva
Lead Sponsor
Universidade Federal do Pará
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Individuals between 30 and 65 years old; both genders; diagnosed with MS according to the criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III, 2001); consulted at the Nutrition Clinic of the João de Barros Barreto University Hospital (HUJBB).

Exclusion criteria

Exclusion criteria: Patients with abnormal thyroid function; chronic kidney and / or liver disease; patients with neurodegenerative diseases such as dementia.

Design outcomes

Primary

MeasureTime frame
It is expected to find a reduction in total cholesterol, LDL-cholesterol, triglycerides, increase in HDL-cholesterol, decrease in fasting glucose and insulinemia, and reduction in C-reactive protein, evaluated by biochemical tests at the beginning and at the end of the study, after finding a statistically significant variation (p-value less than 0.05).;Reduction in lipoperoxidation measurement and improvement in total antioxidant capacity assessed by blood tests before and after 30 days of supplementation, after finding a statistically significant variation (p-value less than 0.05).;Reduction in body mass index and waist circumference assessed by weight and height and waist circumference measurements, respectively, at the beginning and end of the study, after finding a statistically significant variation(p-value less than 0.05).;Reduction in body fat percentage, analyzed by bioelectrical impedance before and after thirty days of supplementation, after finding a statistically significant variation (p-value less than 0.05).;Systolic and diastolic blood pressure reduction, assessed through manual sphygmomanometer calibrated and validated by the National Institute of Metrology, Quality and Technology (INMETRO), using cuff suitable for arm circumferenc. The average value of three measurements will be considered. Measurements will be performed before and after the intervention and the expected reduction will be considered based on the finding of a statistically significant variation (p-value less than 0.05).

Secondary

MeasureTime frame
Secondary outcomes are not expected.

Countries

Brazil

Contacts

Public ContactLívia Costa e Silva

Universidade Federal do Pará

liviacostaesilva@hotmail.com+55 91 3201-8861

Outcome results

None listed

Source: REBEC (via WHO ICTRP)